PTC\SB(08x (08-03)
Approved for use through 07/31/2006 OMB 085-1-2031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
d to a collection of information unless it contains a valid OMB control number.

	Application Number				
INFORMATION DIGGI COURT	Filing Date				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor K. Do		onald Evans		
(Not for submission under 37 CFR 1.99)	Art Unit				
(Not for Submission and or or trively	Examiner Name				
	Attorney Docket Numb	er	14216.16		

	Remove					
Examiner Initial*	Cite No	Patent Number Kind Code <sup>1</sup> Issue Date Name of Patentee or Application of cited Document				Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6737390		2004-05-18	Sunder et al.	
	2	6689276		2004-02-10	Caruthers, Jr.	
	3	6562771		2003-05-13	Finch et al.	
	4	6403551		2002-06-11	Caruthers, Jr. et al.	
	5	6387864		2002-05-01	Bartelme, Michael James	
	6	6365568		2002-04-02	Olson et al.	
	7	6362150		2002-03-26	Lunati	
	8	6301733		2001-10-16	Dawson et al.	

Application Number |
Filing Date |
First Named Inventor | K. Donald Evans |
Art Unit |
Examiner Name |
Adomey Docket Number |
Filing Date |
First Named Inventor | K. Donald Evans |
Art Unit |
Examiner Name |
Adomey Docket Number |
14216.16

9	•	6262004	2001-07-17	Carufhers, Jr. et al.	
1	10	6178987	2001-01-30	Caruthers, Jr. et al.	
1	11	6147577	2000-11-14	Cavey	
1:	12	6063747	2000-05-16	Warwick	
1	13	6032495	2000-03-07	Leu	
1-	14	5962389	1999-10-05	Partee et al.	
1	15	5946951	1999-09-07	Watanabe	
1	16	5924151	1999-07-20	Connan	
1	17	5916866	1999-06-01	Davies et al.	
1	18	5873268	1999-02-23	Spriggs et al.	
1:	19	5870906	1999-02-16	Denisar	

Application Number Fing Date Fing Date
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)
Applicant Number Fing Date
First Number Number K Donald Evans
Art Unit
Examiner Name
Attorney Docket Number 14216.16

20	5839298	1998-11-24	Duquet	
21	5827434	1998-10-27	Yando	
22	5810043	1998-09-22	Grenier	
23	5801137	1998-09-01	Addison et al.	
24	5768917	1998-06-23	Freida	
25	5755330	1998-05-26	Sragusa et al.	
26	5711920	1998-01-27	Barford et al.	
27	5665694	1997-09-30	Backes et al.	
28	5650013	1997-07-22	Gordon et al.	
29	5443751	1995-08-01	Maxxola, Louis R.	
30	5393446	1995-02-28	Matsumoto	

Application Number | Filing Date | First Named Inventor | K Donald Evans | Art Unit | Examiner Name | Attorney Docket Number | 14216.16

31	5355541	1994-10-18	Rutter et al.	
32	5344633	1994-09-01	Sorensson et al.	
33	5338528	1994-08-01	Sorensson et al.	
34	5316692	1994-05-31	John	
35	5310430	1994-05-10	McCall Jr.	
36	5118439	1992-06-02	Urfer et al.	
37	4826661	1989-05-02	Copeland et al.	
38	4753755	1988-06-28	Ganeser	
39	4569780	1986-02-11	Fernholz et al.	
40	4532722	1985-08-06	Sax	
41	4397777	1983-08-01	Yurko, Joseph A.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT														
			First Named Inventor K. Donald Evans											
		NIBY APPLICA ission under 37 CFR 1		Art Un	Art Unit									
(1401101	Subili	ission under 57 GFK I	.001	Examiner Name										
				Attorn	ey Doc	ket Numb	er	1	4216.16					
			_											
	42	3772193		1973-1	1-13	Nelli et al.								
	43	3726304		1973-04	4-10	Cook								
	44	3715314		1973-02	2-06	Morgenstem								
	45	3649545		1972-03	3-14	Suski et al.								
	46	3640876		1972-02	2-08	Donaghu								
	47	3507624		1970-0-	4-21	Schneider, Jr. et al.			1					
If you win	h to o	d additional U.S. Pater	t aitatio	n inform	otion of	noso eliek	the	Add	hutton			Add		_
ir you wisi	n to ac	od additional U.S. Pater				CATION P						Remove	]	
	_		U.S.F	AIENI	AFFLI	ATION	UBL	JUA	IIONS	_		Homovo	ı	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	of cited Document Relev				Releva	es,Columns,Lines where evant Passages or Relevant res Appear			
	1													
	L									Add				
п you wisi	n to a	d additional U.S. Public				•			e Add	button.	Remove			
				FOREIC	on PAT	ENT DOC	UM	ENT	٥		- 1-		,	_
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Coded Dote App			Applicant of cited		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				

Application Number

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Address: Add the Examiner Name Attorney Docket Number 14216.16

1991-11-14

Leshe et al.

wo

	2	2109398	GB		1983-06-02	Unilever PLC			
	3	9804672	wo		1998-02-05	Hall et al.			
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	n Add		
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									
	1								

EXAMINER SIGNATURE

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered, include copy of this form with next communication to applicant.

If you wish to add additional non-patent literature document citation information please click the Add button Add

See Kins Codes of USPTO Patent Documents at swee USPTO\_GOLV or MEPF 04164. Texture date that issued the document, by the No-bittor code (WIPO Standard ST3.) For Uspaneses parted routements, the reducation of the year of the register of the Emport many precise of the smooth name that the patent document. Varied of coursent by the appropriate symbols as endicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark there if Employed in the Course of th

1 9117232

## Application Number Filing Date Filing Date Filing Date First Number I Numbe

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

lorin or the signature.			
Signature	/Evan R. Witt/	Date (YYYY-MM-DD)	2006-08-09
Name/Print	Evan R. Witt	Registration Number	32512

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Afford, U.S. Department of Commence, P. 0. Bast 1450, Alexandria, V.S.231.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.